Mounjaro injection results: what the clinical evidence actually shows

The biggest myth: that 20% is a number most people hit quickly

The figure that circulates most on social media is the peak result from the highest dose over the longest trial period. It is real, but it tells a very specific story. The SURMOUNT-1 participants took 72 weeks (roughly 17 months) to reach those averages, and they were on 15mg for much of that time. The trial started everyone at 2.5mg: a dose designed to let the body adjust, not to produce visible weight loss in week one. Expecting dramatic changes at the starter dose is the most common source of early disappointment our prescribers encounter.

The honest picture is a gradual, dose-dependent curve. Average reductions at 5mg were around 15%; at 10mg closer to 19%; at 15mg around 20–21%. Each step up takes at minimum four weeks, and your prescriber decides the pace based on how you are tolerating the medicine. Rushing titration does not speed up fat loss, it increases the chance of side effects that force a pause. If you want to understand the full injection process before you start, our guide to the Mounjaro injection walks through technique, timing and what to expect week by week.

One more thing the headline number does not show: about 10% of SURMOUNT-1 participants lost 25% or more of their body weight. A smaller proportion lost less than 5%. Biology varies. A clinical assessment considers your starting point, your history and any medicines you are already taking, all of which affect where you land on that curve.

What the injection actually does inside the body to produce those results

Tirzepatide works by activating two receptors simultaneously: GLP-1 (glucagon-like peptide-1) and GIP (glucose-dependent insulinotropic polypeptide). Both are gut hormones released after eating. Activating them together slows gastric emptying, increases the sensation of fullness and reduces appetite signals in the brain, which is why most people on Mounjaro find they simply want to eat less, rather than having to fight hunger through willpower.

It is the only dual-agonist weight-loss medicine licensed in the UK, which is the mechanism most clinicians point to when explaining why its trial results pulled ahead of single-receptor medicines. NICE formally recognised this in Technology Appraisal TA1026, published in December 2024, which recommended tirzepatide for adults with a BMI of 35 or above alongside at least one weight-related condition. The thresholds are 2.5 kg/m² lower for some ethnic backgrounds under UK guidance.

Slower gastric emptying also means the GI side effects that some people experience (nausea, loose stools, occasional vomiting) are a direct consequence of the same mechanism producing the results. They tend to be most noticeable in the first few weeks at a new dose and typically settle. Understanding the mechanism helps make sense of both the benefits and the adjustment period. The detailed results breakdown covers what the data shows at each individual dose level.

Injection site and technique: a small detail with a real effect on consistency

A factor rarely mentioned in results discussions is that where and how you inject affects how reliably the medicine is absorbed. Tirzepatide is given subcutaneously (into the layer of fat beneath the skin) in the abdomen, thigh or upper arm, and choosing the right location can make a meaningful difference to how consistently the medicine is absorbed. Rotating sites reduces the risk of lipohypertrophy (thickened tissue from repeated injections in the same spot), which can impair absorption and subtly blunt results over time.

Our prescribers often tell patients that consistent weekly timing matters more than most people expect. Missing a dose or injecting at irregular intervals can interrupt the steady plasma levels the medicine needs to work. The once-a-week schedule is one reason many people find Mounjaro easier to stick to than daily medicines, though if you are planning a holiday or a bank-holiday week, it is worth checking with your prescriber whether to adjust the day slightly rather than let a dose drift significantly. For a detailed look at which site tends to suit different patients, our guide to the best place to inject Mounjaro for the most consistent results covers the evidence behind each option.

Technique is also why the KwikPen format matters. If you are new to self-injecting, our page on how Mounjaro injection pens work explains the pen's design, how each dose is set and released, and what to check before you use it. Changing the needle before each use is standard practice, and replacement needles are available if you need additional supply between orders. Swabbing the skin before injection is a sensible hygiene step that takes seconds.

How Mounjaro results compare, and where the consultation comes in

The SURMOUNT-5 trial, published in the New England Journal of Medicine in 2025, put tirzepatide head-to-head with semaglutide 2.4mg (Wegovy) in 751 adults with obesity and no diabetes over 72 weeks. Tirzepatide produced a greater average reduction. That is the strongest available direct evidence for the comparison, and NICE's committee discussion for TA1026 noted that indirect comparisons also favoured tirzepatide.

This does not mean Wegovy is ineffective, or that Mounjaro is the right choice for every person. Eligibility, other medicines, personal preference for injection versus tablet, and clinical history all shape which treatment a prescriber recommends. Understanding the cost context is often part of that conversation too; our Mounjaro cost page explains what private treatment involves and what a quoted price should include.

If you have questions about whether these results are realistic for your situation, the right place to start is a clinical consultation rather than a trial average. Speak to our prescribers through a free consultation, a GPhC-registered Independent Prescriber reads your answers the same day and can tell you whether Mounjaro is clinically suitable for you.